Joanne Murray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joanne Murray has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chris Gale
Neonatal Medicine, School of Public Health, Imperial College London, London, UK
2 shared publications - David Churchill
Department of Obstetrics, The Royal Wolverhampton National Health Service Trust, New Cross Hospital, Wolverhampton, United Kingdom
2 shared publications - Stephanie J. Lax
Department of Lifespan and Population Health, School of Medicine, University of Nottingham , Nottingham
2 shared publications - Andrew Farmer
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
1 shared publication Cara Hudson
Department of Statistics and Clinical Research, National Health Service Blood and Transplant Clinical Trials Unit, National Health Service Blood and Transplant, Bristol, United Kingdom
1 shared publication- Elise Crayton
Centre for Behaviour Change, University College London, UK
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by UCL Press in Research for All
- Vol. 10 (1)
Working towards better informed consent: service user-led exploration of women’s views on data linkage on behalf of their unborn child(ren)
This paper outlines how service user co-investigators worked towards achieving informed consent to data linkage in a large-scale clinical trial in pregnancy with long-term developmental outcomes. The PANDA (Primary prevention of maternal ANaemia to avoid preterm Delivery and other Adverse outcomes) programme tests whether prevention of anaemia during pregnancy reduces adverse clinical complications such as preterm birth and low birth weight. One component is a randomised trial of 11,000 women taking oral iron from early in pregnancy versus placebo. Collection of infant and childhood data by linkage to relevant national datasets will enable efficient and robust assessment of key long-term developmental outcomes. Faced with the challenge of informing women’s consent, service user investigators have been proactive and adaptive in leading the development of women-facing materials. First, service user co-investigators consulted women to determine the breadth of issues important to them when considering consenting to PANDA. Then, they produced draft materials tailored to women’s information needs, prioritising information accessibility. Subsequently, they lobbied for, and led, additional focus groups with women from PANDA’s pilot trial to seek feedback on the bespoke materials and gauge the extent to which women understood the content and issues being expressed.
- 14 January 2026
- Published by UCL Press in Research for All
- Vol. 10 (1)
Open AccessWorking towards better informed consent: service user-led exploration of women’s views on data linkage on behalf of their unborn child(ren)
This paper outlines how service user co-investigators worked towards achieving informed consent to data linkage in a large-scale clinical trial in pregnancy with long-term developmental outcomes. The PANDA (Primary prevention of maternal ANaemia to avoid preterm Delivery and other Adverse outcomes) programme tests whether prevention of anaemia during pregnancy reduces adverse clinical complications such as preterm birth and low birth weight. One component is a randomised trial of 11,000 women taking oral iron from early in pregnancy versus placebo. Collection of infant and childhood data by linkage to relevant national datasets will enable efficient and robust assessment of key long-term developmental outcomes. Faced with the challenge of informing women’s consent, service user investigators have been proactive and adaptive in leading the development of women-facing materials. First, service user co-investigators consulted women to determine the breadth of issues important to them when considering consenting to PANDA. Then, they produced draft materials tailored to women’s information needs, prioritising information accessibility. Subsequently, they lobbied for, and led, additional focus groups with women from PANDA’s pilot trial to seek feedback on the bespoke materials and gauge the extent to which women understood the content and issues being expressed.
- Open Access
- 1 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (21) , 5683-5694
The impact of different doses of oral iron supplementation during pregnancy: a pilot randomized trial
Oral iron is first-line medication for iron deficiency anemia in pregnancy. We conducted a pilot randomized trial to investigate the impact of different doses of oral iron supplementation started early in pregnancy on women without anemia for 4 main outcomes: recruitment and protocol compliance, adherence, maintenance of maternal hemoglobin, and side effects. At antenatal clinic visits, participants were allocated to 1 of 3 trial arms in a 1:1:1 ratio: 200 mg ferrous sulfate daily, alternate days, or 3 times per week. The participants were followed to delivery. Baseline characteristics of 300 recruited participants were well matched between trial arms. The mean proportion of tablets taken as expected per participant was 82.5% overall (72.3%, 89.6%, and 84.5% for the daily, alternate days, and 3 times a week arm, respectively). There was a lower overall adherence rate in the daily arm (47%) than in the alternate days (62%) and the 3 times per week (61%) arms. A reduction in hemoglobin between randomization and 28 weeks’ gestation seemed smaller for the daily arm. A range of side effects were commonly reported at baseline before starting interventions and at later antenatal visits. Many side effects of iron overlapped with normal pregnancy symptoms. A daily iron dosing schedule might give the best opportunity for delivering an adequate iron load during pregnancy in women without anemia. Further randomized trials powered on clinical outcomes are needed to establish the clinical effectiveness of oral iron supplementation to prevent iron deficiency anemia. This study was registered (#ISRCTN12911644).
- 1 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (21) , 5683-5694
Open AccessThe impact of different doses of oral iron supplementation during pregnancy: a pilot randomized trial
Oral iron is first-line medication for iron deficiency anemia in pregnancy. We conducted a pilot randomized trial to investigate the impact of different doses of oral iron supplementation started early in pregnancy on women without anemia for 4 main outcomes: recruitment and protocol compliance, adherence, maintenance of maternal hemoglobin, and side effects. At antenatal clinic visits, participants were allocated to 1 of 3 trial arms in a 1:1:1 ratio: 200 mg ferrous sulfate daily, alternate days, or 3 times per week. The participants were followed to delivery. Baseline characteristics of 300 recruited participants were well matched between trial arms. The mean proportion of tablets taken as expected per participant was 82.5% overall (72.3%, 89.6%, and 84.5% for the daily, alternate days, and 3 times a week arm, respectively). There was a lower overall adherence rate in the daily arm (47%) than in the alternate days (62%) and the 3 times per week (61%) arms. A reduction in hemoglobin between randomization and 28 weeks’ gestation seemed smaller for the daily arm. A range of side effects were commonly reported at baseline before starting interventions and at later antenatal visits. Many side effects of iron overlapped with normal pregnancy symptoms. A daily iron dosing schedule might give the best opportunity for delivering an adequate iron load during pregnancy in women without anemia. Further randomized trials powered on clinical outcomes are needed to establish the clinical effectiveness of oral iron supplementation to prevent iron deficiency anemia. This study was registered (#ISRCTN12911644).